L01EX08 • lenvatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors
Lenvatinib is a medication used to treat certain types of cancer, including thyroid cancer, hepatocellular carcinoma, and renal cancer. It is a tyrosine kinase inhibitor that works by blocking signals that promote tumor growth and the formation of new blood vessels.
The medication is taken orally, usually once daily, and the dosage is adjusted based on body weight and the type of cancer being treated. Treatment is carried out under the supervision of an oncologist.
Side effects may include high blood pressure, fatigue, diarrhea, loss of appetite, and abdominal pain. In rare cases, severe adverse effects such as liver or kidney failure may occur.
Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should not use this medication.
Substance: lenvatinib
Date of last drug list: 01-01-2026
Commercial code: W71574001
Concentration: 4mg
Pharmaceutical form: capsules
Quantity: 30
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: SYNTHON HISPANIA S.L. - SPANIA
Holder: EGIS PARMACEUTICALS PLC - UNGARIA
Number: 16335/2025/01
Shelf life: 2 years